Cerus Corporation

NASDAQ:CERS

Medical - Devices

Healthcare
$1.94 +2.92%

+$0.08 today

Market cap
$391.79M
Beta
1.77
P/E (TTM)
-53.8
EPS (TTM)
-$0.05
52W Low $1.15High $3.15

Volume 6.09M

Average 2.33M

CERS Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Cerus CorporationNASDAQ: CERS

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit growth accelerates

Q1 FY2026 gross profit of $34.13M rose 34.2% year over year, ahead of the +16.7% change in trailing-twelve-month gross profit. Sequentially, it rose 14.7% from the prior quarter. Over 3 fiscal years it compounded at +8.2% a year.

Context

  • Gross profit amounted to 53.5% of revenue in FY2025, down 1.7 pp from a year earlier.
  • Gross profit increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +34.2% holds above the trailing-twelve-month pace of +16.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$34.13M+14.7% QoQ
Last fiscal yearDec 2025
$110.29M+10.8% YoY
LTMMar 2026
$120.99M+16.7% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+34.2%——
1 year+10.8%——
3-year CAGR+8.2%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
110.29M USD
Year-over-year change
+10.8%
4-year CAGR
+13.1%

Gross Profit vs competitors

How CERS compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +16.7% is the 2nd highest of 4, against a peer median of +1.4%.
  • Gross profit amounts to 54.3% of revenue for CERS, versus a peer median of 57.4%.
CERS Competitors
Gross Profit for CERS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GRFSGrifols, S.A.LTM Jun 2026€2.77B EUR-6.0%+5.2%37.2%
HAEHaemonetics CorporationLTM Jun 2026$775.84M USD+1.4%+6.1%57.4%
ADMAADMA Biologics, Inc.LTM Jun 2026$331.47M USD+31.9%+102.5%64.7%
CERSCerus CorporationLTM Mar 2026$120.99M USD+16.7%+8.2%54.3%
Peer median (excluding CERS) —+1.4%+6.1%57.4%

Competitors are the stored peer set for CERS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue130.86M162.05M156.37M180.27M206.13M
Cost of Revenue63.48M74.95M69.97M80.75M95.85M
Gross Profit67.38M87.09M86.4M99.52M110.29M
Gross Margin51.5%53.7%55.3%55.2%53.5%
Research & Development63.69M64.11M67.64M58.91M65.72M
Selling, General & Admin81.29M83.34M75.52M75.89M80.91M
Operating Expenses116.32M121.18M116.45M113.75M146.63M
Depreciation & Amortization3.15M2.98M2.6M1.86M2M
EBITDA(45.99M)(33.52M)(26.34M)(10.02M)(4.94M)
EBITDA Margin-35.1%-20.7%-16.8%-5.6%-2.4%
Operating Income(48.94M)(34.08M)(30.05M)(14.23M)(36.35M)
Operating Margin-37.4%-21.0%-19.2%-7.9%-17.6%
Interest Income00000
Interest Expense4.92M5.83M8.39M8.88M8.34M
Other Income / Expenses(5.12M)(8.26M)(7.27M)(6.53M)21.06M
Income Before Tax(54.06M)(42.34M)(37.32M)(20.76M)(15.28M)
Pre-Tax Margin-41.3%-26.1%-23.9%-11.5%-7.4%
Income Tax Expense319K488K325K205K354K
Net Income(54.37M)(42.78M)(37.49M)(20.92M)(15.63M)
Net Margin-41.6%-26.4%-24.0%-11.6%-7.6%
EPS (Basic)(0.32)(0.24)(0.21)(0.11)(0.08)
EPS (Diluted)(0.32)(0.24)(0.21)(0.11)(0.08)
Weighted Avg Shares171.28M176.55M180.27M184.56M190.59M
Weighted Avg Shares (Diluted)171.28M176.55M180.27M184.56M190.59M

Cerus Corporation

NASDAQ:CERS

Intrinsic Alpha fair value

Locked

Current Price

$1.94

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.